2024 - Targeted Therapies: The Role of Large Molecules, Biologics and ADCs

Discover an insightful webinar on the latest advancements in biologics, with a special focus on antibody-drug conjugates (ADCs) and their role in transforming targeted therapies.
In this webinar, the attendees will get to learn how patient-derived models and large biobanks are driving novel target discovery, therapeutic evaluation and biomarker discovery, all aimed at improving clinical outcomes and reducing off-target effects. The expert speaker will explore the seamless generation of biologics, including antibodies, ADCs, bispecifics and peptides, backed by comprehensive in vitro and in vivo efficacy testing.
Real-world case studies will showcase how an integrated platform can help streamline drug development, from target discovery to clinical translation, and offer flexible, customizable solutions to meet specific project needs.
By attending this webinar, attendees will discover how to:
Leverage patient-derived models for novel target discovery and biomarker identification
Generate and optimize biologics for biochemical characterization and efficacy testing
Utilize flexible services to accelerate drug development pipelines
Register for this webinar today to learn how to enhance biologics and ADC development programs with cutting-edge technologies and transform the development of targeted therapies.
Keywords: Drug Development, Targeted Therapy, Drug Discovery, Clinical Research, CRO, Oncology,  Oncology Drugs, Therapeutic Areas, Antibody-Drug Conjugate, Basic Research, Bispecific Antibody